74 Gu FL, Cai SL, Cai BJ, Wu CP. Cellular origin of renal cell carcinoma--an immunohistological study onmonoclonal antibodies. Scand J Urol Nephrol Suppl. 1991;(Suppl);138:203-6. Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med.2010;61:329-343. Rankin EB, Fuh KC, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci USA. 2014;111(37):13373-13378. de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A. 2001;98:1387-92. Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the plateletderived growth factor-B chain gene in human endothelial cells. J Clin Invest. 1990;86:670-4. Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2010;10(7):658-664. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263-1284. De Luca A, Carotenuto P, D’Alessio A, Normanno N. Molecular biology of renal-cell carcinoma. EJC Supplements. 2008;6(14):30-34. Graves A, Hessamodini H, Wong G, Lim WH. Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. ImmunoTargets and Therapy. 2013;2:73-90. Rankin EB y Giaccia AJ. The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers. 2016;8:103. Roy S, Narang BK, Rastogi SK, Rawal RK. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib. Anticancer Agents Med Chem. 2015;15(1):37-47. Boysen G, Bausch-Fluck D, Thoma CR, et al. Identification and functional characterization of pVHLdependent cell surface proteins in renal cell carcinoma. Neoplasia. 2012;14(6):535-546. Zhou L et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Oncogene. 2016b;35(21):2687-97. Pinato DJ. TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene. 2016 May;35(21):2684-6. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090-100. 1Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2015.Oncogene. 2016;35(21):2687-97. Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343-349. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386. American Cancer Society. Kidney Cancer (Adult) - Renal Cell Carcinoma, 2016. Disponible en:http://www.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-30. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193-205. Jove M, et al. Clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving several lines of target therapy: retrospective analyses of a cohort of three multidisciplinary centres from Spain. ESMO Congress. Madrid, Spain 2014. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913-24